Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
about
Radiotherapy versus combined modality therapy for anal carcinomaHematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective.Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11)US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.Perioperative radiotherapy in rectal cancer.Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional dataSafety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institutionImpact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity.Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canalRecent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncologyOctreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinomaTechnical aspects of radiation therapy for anal cancer.Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature.Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma.Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA).Spatial mapping of functional pelvic bone marrow using FLT PET.Multimodality therapy in penile cancer: when and which treatments?Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer.Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature.Anal cancer treatment: current status and future perspectives.RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canalRadiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapyHIV- positive anal cancer: an update for the clinicianRadiosensitizers in cervical cancer. Cisplatin and beyond.Anal canal carcinoma treatment results: the experience of a single institution.Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review.Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexualsThe Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series
P2860
Q24247566-C0E9E66C-91C9-4C85-A0F6-ADA77AF0EFBBQ30235359-DA584F66-6181-49D5-8A39-C26D427C9BB5Q30409533-72A268FB-EEA0-4A6F-9BF6-BC1EEA32E299Q30415832-C4A473AE-A6A4-404C-BB06-350A8F43CE14Q30416301-B02897FF-4F52-4218-97F6-DC04A7B43B12Q30436928-E0717C14-7E81-428A-8DB2-7528D79C5874Q32160328-A28C5B73-EA00-40E8-9251-D53841A948B5Q33314684-9A5FDA47-A313-4AB8-B661-C97226B0C733Q33431168-F8C762B5-D8B3-4BCB-A684-ACD814505248Q33544644-51714222-2AC6-474E-8BAD-1FD52B398271Q33578833-3426144A-BDB3-4A04-8323-6E66B6EF4B7EQ33608156-2703122C-6485-4847-AF2C-21572C31CCD8Q33646367-E9EF79D7-91AA-4B72-B7CD-E499A46A9980Q33702377-EC3693C4-AB04-4B54-9341-EF508244839BQ33721749-47274F9E-3074-4F04-9D36-BF0F0B07C252Q33729819-2B92C69F-8B4B-4345-A2B2-300FEC8340D6Q33763918-8B43218F-8A33-4840-9E6D-0F3C34F9D1D5Q33783068-0E0D84EE-A1F0-407B-8FB8-5084472480D9Q33787728-502B8433-009C-4911-BBFC-B25E24DE9750Q33797364-05D7E8AA-BC89-43A5-A141-38DAC3D6C83CQ33803090-C329DD58-8BFE-4675-861C-A272B91F35E6Q33811309-5E391E66-7DA9-4E95-B8C0-8BA4B0C0FE2AQ33820797-4DAE3050-30E8-4FD5-9081-205B4CFCF055Q33888085-D533324B-411B-44F7-B9F9-C258CE24FE4DQ33905348-903A64EF-B1CA-4369-9FE4-12E3980C0B07Q34074596-544B9C8F-21E3-46EE-B97D-5DF7AD64AB31Q34169627-13E1213C-B292-4F87-8E74-E667F6658EECQ34182566-30697220-119C-4B2E-9EF3-CBE0118F5A0CQ34246244-3778AED0-3D6F-4826-8B39-C91EF56D1199Q34302253-DB5993B8-D16B-4080-A578-05C62CDAF517Q34465769-B4E18DBC-001E-4F7E-8CA8-D422199FF8CEQ34478729-86F5D9BE-8947-4291-9800-DD15BBB9EAB2Q34584811-85189F47-F757-4106-97EF-DAB0D9516144Q34640551-A932CC32-ABA8-4266-8016-5EA5D16F85E5Q34684307-004F33AE-725C-495F-A1D3-EBB68C5C0B32Q35008645-3C347F0C-A367-4E36-9737-0CFC4A464D00Q35039830-2BB60A41-1D39-467B-8084-1ADDC060A482Q35086388-C43D9A21-05C6-46DF-B774-8E7AEA85315FQ35093611-714C9A43-04D7-4B7B-B61C-E1A8423BBFB7Q35104586-C0665E2E-C7F7-4272-850C-7AF265C7C597
P2860
Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Role of mitomycin in combinati ...... I randomized intergroup study.
@en
Role of mitomycin in combinati ...... I randomized intergroup study.
@nl
type
label
Role of mitomycin in combinati ...... I randomized intergroup study.
@en
Role of mitomycin in combinati ...... I randomized intergroup study.
@nl
prefLabel
Role of mitomycin in combinati ...... I randomized intergroup study.
@en
Role of mitomycin in combinati ...... I randomized intergroup study.
@nl
P2093
P1476
Role of mitomycin in combinati ...... I randomized intergroup study.
@en
P2093
N Petrelli
P304
P356
10.1200/JCO.1996.14.9.2527
P407
P577
1996-09-01T00:00:00Z